常山药业：依诺肝素钠注射液获得美国药品注册批准

Core Viewpoint - The company Changshan Pharmaceutical has received approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Enoxaparin Sodium Injection, which is used for various medical conditions related to thrombosis [1] Group 1 - The approved drug, Enoxaparin Sodium Injection, is indicated for the prevention of venous thromboembolic diseases, particularly those associated with orthopedic or general surgery [1] - It is also used for the treatment of established deep vein thrombosis, with or without pulmonary embolism [1] - The drug can be used in combination with aspirin for the treatment of unstable angina and non-ST elevation myocardial infarction [1] - Additionally, it is utilized in hemodialysis to prevent thrombosis during extracorporeal circulation [1]